Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT06727201
Starting soon Phase 2/3

Role of Ondansetron in Spinal Anaesthesia Induced Hypotension

NCT06727201 · tracked via the Priya Life Science Egypt tracker
Sponsor
Assiut University
Phase
Phase 2/3
Started
2025-01-01
Last updated
2024-12-10

Condition(s) studied

Spinal Anaesthesia Induced Hypotension

Investigational drug(s) / intervention(s)

Ondansetron (Zofran) →Saline (NaCl 0,9 %) (placebo)

Ondansetron (Zofran): Ondansetron will be given intravenously in a dose of 0.1mg/kg 10 minutes before spinal anaesthesia as single shot.

Saline (NaCl 0,9 %) (placebo): normal saline infusion will be given intravenously 10 minutes before spinal anaesthesia

Study summary

The objective of this study is to determine the effect of ondansetron on the total consumption of norepinephrine infusion needed to prevent spinal anaesthesia induced hypotension in cesarean section.

Eligibility

Sex
FEMALE
Min age
19 Years
Max age
40 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age from 19 to 40 years old. * Singleton pregnancies with a gestational age of at least 37 weeks. * pregnant women are scheduled for elective caesarean delivery. * Patients with stable vital signs. * Patients with normal laboratory investigations. * patients undergoing spinal anaesthesia for caesarean delivery via Pfannenstiel incision with exteriorizaion of the uterus. Exclusion Criteria: * Patient's refusal. * Age \< 19 or \> 40 years. * Height\<150 cm, weight \< 60 kg, body mass index (BMI) ≥40 kg/m2. * Contraindications to spinal anaesthesia (Coagulopathy, increased intracranial pressure, or local skin infection). * Patients with cardiac morbidities. * hypertensive disorders of pregnancy as pre-eclampsia. * peripartum bleeding. * Patients with respiratory morbidities. * Convulsions. * Bleeding diathesis. * Known allergy to any drugs used in this study.

Primary outcome measure(s)

  • Total consumption of norepinephrine during the whole surgical procedure. — Just after subarachnoid block till the end of surgery
    Comparison between total amount of vassopressor used to maintain normal blood pressure in both groups of study

Trial sites (1)

FacilityCityRegionStatus
Assiut university Asyut Egypt

More Assiut University trials in Egypt

Combined Hystroscopic and Laparoscopic Repair of CS Scar Disorder Recruiting
The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion Starting soon
Maternal Iron Deficiency and/or Iron Deficiency Anemia to Neonatal Hemoglobin Concentration and Iron Stores Starting soon
Real-Time (TRUS) Guidance in Endoscopic Treatment of BPH Starting soon
Intraoperative Lidocaine Infusion Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06727201 on ClinicalTrials.gov ↗ ← All trials in Egypt